# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
TD Cowen analyst Daniel Brennan maintains Standard BioTools (NASDAQ:LAB) with a Buy and lowers the price target from $3.5 to...
Alex Kim, the Company's Chief Operating Officer and co-founder of Standard BioTools, will serve as Standard BioTools' i...